Maynard Um
-
-
-
-
-
-
-
Merck & Co Inc: Intismeran Plus Keytruda Significantly Reduced The Risk Of Recurrence Or Death By 42% Compared To Keytruda Alone - Reuters
-
-
-
-
-
-
-
Merck (MRK) PT Raised to $145 at Citi
-
-
-
-
-
-
-
Merck and Daiichi Sankyo withdraw lung cancer drug application
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
-
-
-
-
-
-
Merck (MRK) call put ratio 1.4 calls to 1 put into INTerpath-001 trial results
-
-
-
-
-
-
-
Merck (MRK) Tops Q2 EPS by 14c, Beats on Revenue; Offers FY26 EPS Guidance
-
-
-
-
-
-
-
Gilead to present lenacapavir HIV trial data at AIDS 2026
-
471,214 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


